Ross Acquisition Corp II
ROSS-UN
New York Stock Exchange11.00
USD
-0.08
- -
Ross Acquisition Corp II
ROSS-UN
(New York Stock Exchange)
Recent
price
11.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ross Acquisition Corp II is a special purpose acquisition company (SPAC) primarily engaged in identifying and acquiring one or more businesses or assets through mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations. Founded in 2021 and headquartered in Palm Beach, Florida, the company focuses on business combinations within traditional industries influenced by the fourth industrial revolution including automotive (electric and autonomous vehicles), energy (storage, renewables, and efficiency), manufacturing (automation, robotics, AI, big data, and smart factories), materials (chemicals and sustainable materials), semiconductors, space technology, and transportation sectors with data analytics and alternative fuels. Ross Acquisition Corp II aims to operate primarily in North America, Europe, and Asia. The company completed its initial public offering in March 2021, raising approximately $345 million. Ross Acquisition Corp II has been sponsored by Ross Holding Company LLC, an affiliate of Wilbur L. Ross, Stephen J. Toy, and Nadim Z. Qureshi. A major recent development includes entering into a definitive business combination agreement with APRINOIA Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer’s Disease and Progressive Supranuclear Palsy. This merger is structured at an implied fully diluted equity value of $280 million for APRINOIA, with significant capital investments from Wilbur Ross and other investors intended to commercialize APRINOIA's lead product, 18F-APN-1607, particularly for the China market. In the past year, Ross Acquisition Corp II has faced important operational changes, including the suspension and expected de-listing from the New York Stock Exchange and plans to seek listing on the Nasdaq Stock Market. The company holds substantial funds in its trust account intended for business combinations. Overall, Ross Acquisition Corp II functions as a financial conglomerate and a SPAC with strategic moves geared toward high-growth sectors shaped by technological innovation and global industrial transformation. Its primary product offering is the execution of acquisition and merger transactions specializing in targeted industries, with a current focus on biopharmaceutical technologies via the APRINOIA partnership. This description synthesizes the company’s core activities and recent strategic developments including its SPAC acquisition focus, latest business combination, and market listing changes. Ross Acquisition Corp II operates across multiple continents with an emphasis on leveraging emerging industrial technologies through capital market transactions and acquisitions led by seasoned financial sponsors.